Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 516 of 5804
-
New hope for tough lung cancer: drug combo targets liver spread
Disease control Recruiting nowThis clinical trial aims to assess whether the addition of bevacizumab to atezolizumab and chemotherapy can improve response to treatment and progression-free survival in patients with extensive-stage small cell lung cancer (ES-SCLC) with liver metastases. The main questions it …
Phase: PHASE2 • Sponsor: Kamya Sankar • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Which blood thinner combo best prevents a second stroke?
Disease control Recruiting nowAlong with the current clinical trial, the efficacy and safety of a 180 mg loading dose of ticagrelor administered within 24 hours of the first-ever large-vessel minor stroke or TIA compared to 200mg cilostazol were assessed through NIHSS, mRS, and possible adverse effects.
Phase: PHASE3 • Sponsor: Kafrelsheikh University • Aim: Disease control
Last updated Jun 26, 2026 18:36 UTC
-
Can adding venetoclax let CLL patients pause therapy?
Disease control OngoingThe main purpose of the study is to evaluate if adding venetoclax to participants receiving cBTKi for the 1L CLL can achieve deep durable remissions of undetectable measurable residual disease \[uMRD \< or 10\^-4 in peripheral blood (PB)\] by end of combination treatment (EOCT) t…
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New hope for advanced breast cancer: could a biosimilar match the standard?
Disease control OngoingThe main purpose of this study is to prove non-inferiority, as well as to demonstrate the comparability of safety and immunogenicity of RPH-051 and Perjeta® in combination with trastuzumab and docetaxel as the 1st line therapy for patients with HER2-positive breast cancer (BC). S…
Phase: PHASE3 • Sponsor: R-Pharm • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Can a simple test spot sudden-onset neuropsychiatric syndrome in kids?
Knowledge-focused Recruiting nowPediatric Acute-onset Neuropsychiatric Syndrome (PANS) is a complex neuropsychiatric disorder characterized by the abrupt onset of symptoms and currently diagnosed mainly on clinical criteria, as reliable diagnostic biomarkers are still lacking. The primary objective of this proj…
Sponsor: University of Cagliari • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
New drug aims to stop CMV from coming back after transplant
Disease control Recruiting nowThis study is designed to assess how effective letermovir is in preventing recurrence of cytomegalovirus (CMV) infection in adult kidney or kidney/pancreas transplant recipients who are UW Health patients. Participants will be in the study for about 6 months.
Phase: PHASE3 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New vaccine aims to train immune system against HPV cancers
Disease control Recruiting nowThe goal of this clinical trial is to learn about the safety and efficacy of a potential new treatment called Lenti-HPV-07 in patients with a cancer induced by Human Papilloma Virus (HPV). The main questions aim to answer are: * Is Lenti-HPV-07 safe? * Does Lenti-HPV-07 induce …
Phase: PHASE1, PHASE2 • Sponsor: Theravectys S.A. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New hope for kids with Crohn's: oral drug trial launches
Disease control Recruiting nowCrohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the bowels. It can cause many different symptoms including abdominal pain, diarrhea, tiredness, and weight loss. This study will assess…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New combo targets Hard-to-Treat lung cancer mutation
Disease control Recruiting nowThis phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (stage IV) or that has come ba…
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New biosimilar RPH-002 takes on erbitux in head and neck cancer showdown
Disease control CompletedThe primary objective of the study is to evaluate the comparability of efficacy, safety, and immunogenicity of RPH-002 and Erbitux® when administered in combination with docetaxel and cisplatin as first-line therapy in patients with advanced head and neck squamous cell carcinoma
Phase: PHASE3 • Sponsor: R-Pharm • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New hope for tough-to-treat pancreatic cancer? drug combo enters phase 2 trial
Disease control OngoingThe goal of this research study is to asses the safety and efficacy of the combination of AGEN1423 and Botensilimab with or without chemotherapies, gemcitabine and nab-paclitaxel, for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC) which has progressed after at …
Phase: PHASE2 • Sponsor: Bruno Bockorny • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New biologic drug netakimab tested in kids with psoriasis
Disease control OngoingThe aim of the study is to evaluate the efficacy and safety of netakimab compared with placebo in a pediatric population of subjects over 6 years of age with moderate to severe plaque psoriasis. The study will have randomized, double-blind, placebo-controlled study with open-arm …
Phase: PHASE3 • Sponsor: Biocad • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Brain-Spray chemo cocktail targets breast Cancer's deadliest spread
Disease control Recruiting nowEvaluate the efficacy and safety of Intrathecal Administration of Thiotepa in Combination with Methotrexate via the Ommaya Reservoir in Breast Cancer with Leptomeningeal Metastasis
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Promising cocktail aims to shrink esophageal tumors before surgery
Disease control Recruiting nowEsophageal cancer is a prevalent digestive tract tumor, with around 400,000 new cases and 300,000 deaths globally each year. In the past few decades, surgery, radiotherapy, chemotherapy and other treatments were continuously improved, however, the mortality of esophageal squamous…
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New immunotherapy cocktails aim to shrink tough lung tumors
Disease control OngoingThis is a Phase 1b/2 study evaluating the anti-PD1 antibody, cemiplimab, in combination with either S095018 (anti-TIM3 antibody), S095024 (anti-CD73 antibody), or S095029 (anti-NKG2A antibody) in adult participants with previously untreated advanced/metastatic non-small cell lung…
Phase: PHASE1, PHASE2 • Sponsor: Servier Bio-Innovation LLC • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
One-Shot gene therapy could replace monthly eye injections for wet AMD
Disease control OngoingThis will be a clinical study to assess initial safety and tolerability of IVT ABI-110 in patients diagnosed with wet macular degeneration (wAMD), including symptomatic macular PCV.
Phase: PHASE1, PHASE2 • Sponsor: Avirmax Biopharma Inc • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Experimental cocktail aims to tackle returning brain tumors
Disease control OngoingThis study consists of 2 portions. The phase 2 portion is an open-label, single-arm study to evaluate the safety and efficacy of NAI, PD-L1 t-haNK, and bevacizumab combination therapy in participants with recurrent or progressive GBM. The phase 2B portion is an open-label, random…
Phase: PHASE2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Can Ultrasound-Guided healing beat standard care for Crohn's?
Disease control Recruiting nowTransmural healing (TMH) is recognized as a potentially important measure of Crohn's disease (CD) activity but not a formal target. Observational studies suggest that TMH may be associated with better long-term outcomes. The study will evaluate TMH using noninvasive intestinal ul…
Phase: PHASE4 • Sponsor: Alimentiv Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New eye drug EYE103 takes on lucentis in major trial for Diabetes-Related vision loss
Disease control OngoingEYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME) In the first year, all 3 treatment groups will be treated eve…
Phase: PHASE2, PHASE3 • Sponsor: EyeBiotech Ltd. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Parkinson's patients get brain transplants of their own cells
Disease control ENROLLING_BY_INVITATIONThis research study is evaluating an investigational cell product called autologous induced pluripotent stem cell (iPSC)-derived dopamine neurons. This research study is a single-center Phase 1/2a clinical trial, which will test the safety of injecting the investigational cell pr…
Phase: PHASE1 • Sponsor: Penelope J. Hallett, Ph.D. • Aim: Disease control
Last updated Jun 26, 2026 16:38 UTC